AR064547A1 - Derivados de azaspiro como antagonistas del receptor v1a - Google Patents
Derivados de azaspiro como antagonistas del receptor v1aInfo
- Publication number
- AR064547A1 AR064547A1 ARP070105915A ARP070105915A AR064547A1 AR 064547 A1 AR064547 A1 AR 064547A1 AR P070105915 A ARP070105915 A AR P070105915A AR P070105915 A ARP070105915 A AR P070105915A AR 064547 A1 AR064547 A1 AR 064547A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- optionally substituted
- alkoxy
- haloalkyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 27
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- -1 nitro, hydroxy Chemical group 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente está relacionada con derivados de indol-3-il-carbonil-azaspiropiperidina como antagonistas del receptor V1a, con su elaboracion, con composiciones farmacéuticas que los contienen y su utilizacion como medicamentos. Los compuestos activos de la presente son utiles en la prevencion y/o tratamiento de la ansiedad, y trastornos depresivos y otras enfermedades. Reivindicacion 1: Un compuesto con la formula general (1) en el que U es O y V es CH2, o U es O y V es C=O, o U es CH2 y V es O, o U-V es -CH=CH-, o U-V es -CH2-CH2-, o U es CH2, V es NR7; o U es C=O y V es NR7, o U es C=O y V es O; una o dos de las variables W, X, Y y Z son nitrogeno, siendo el resto de las variables CR8; R1es H, alquilo C1-12, opcionalmente sustituido con CN u OH, haloalquilo C1-6, alquenilo C2-12, -(CRiRii)m-Ra, en el que Ri y Rii son independientemente el uno del otro H, metilo, o etilo; en el que m es de 0 a 4; en el que Ra es fenilo, heteroarilo de 5 o 6 miembros, heterocicloalquilo de 3 a 7 miembros o cicloalquilo de 3 a 7 miembros, que están opcionalmente sustituidos con uno o más A, -NRbRc, en el que Rb y Rc son cada uno independientemente hidrogeno, hidroxi, alquilo C1-6, -S(O)2-alquilo C1-6, o -C(O)-alquilo C1-6, -(CRiiiRiv)n- C(O)Rd, en el que Riii y Riv son independientemente eludo del otro H, metilo o etilo; en el que n es de 0 a 4; en el que Rd es: alcoxi C1-6, -NReRf, en el que Re y Rf son cada uno independientemente hidrogeno, alquilo C1-6, o -alquileno C2-6-NRgRh; en el que Rg y Rh son cada uno independientemente hidrogeno, alquilo C1-6, o -C(O)O-alquilo C1-6, fenilo, heteroarilo de 5 o 6 miembros, heterocicloalquilo de 3 a 7 miembros o cicloalquilo de 3 a 7 miembros, que está opcionalmente sustituido con uno o más A, -S(O)2-fenilo, en el que fenilo está opcionalmente sustituido con uno o más halo, haloalquilo C1-6, alquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitro, hidroxi o ciano; -S(O)2-alquilo C1-6, -S(O)2-N(alquilo C1-6)2, -S(O)2-NH(alquilo C1-6); A es halo, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, cianoalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, -S(O)0-2-alquilo C1-6, nitro, hidroxi, ciano, -alquileno C1-6-O-alquilo C1-6, -alquileno C1-6-O-haloalquilo C1-6, -alquileno C1-6-OR''', - C(O)O-alquilo C1-6, -C(O)-alquilo C1-6, -C(O)OR''', -C(O)R''', -C(O)NR'R'', -S(O)2NR'R'', -(CH2)x-NR'R'', -(CH2)x-NR'C(O)-alquilo C1-6, -(CH2)x-NR'S(O)2-alquilo C1-6, -(CH2)x-cicloalquilo C3-6, -(CH2)x-Rö', en los que x es de 0 a 4, R' y R'' son cada uno independientemente H o alquilo C1-6, o R' y R'' junto con el nitrogeno, al que están unidos, forman un heterociclo de 5 o 6 miembros que comprende uno o dos heteroátomos seleccionados de entre N, O o S, y R''' es fenilo o heteroarilo de 5 o 6 miembros, opcionalmente sustituidos con uno, dos o halo, haloalquilo C1-6, alquilo C1-6, o alcoxi C1-6, R2 es hidrogeno, alquilo C1-6, -C(O)Rn, en el que Rn es: alquilo C1-6, heterocicloalquilo de 3 a 7 miembros, opcionalmente sustituido con uno, dos o tres alquilo C1-6, -C(O)O-alquilo C1-6, o -S(O)2-alquilo C1-6, NRjRk, en el que Rj y Rk son cada uno independientemente hidrogeno, alquilo C1-6, -alquileno C2-6-NRlRm; en el que Rl y Rm son cada uno independientemente hidrogeno, alquilo C1-6 o -C(O)O-alquilo C1-6; R3, R4, R5, R6 son cada uno independientemente hidrogeno, halo, alquilo C1-6, halo-alquilo C1-6, alcoxi C1-6 o halo-alcoxi C1-6;o R1 y R6 junto con el anillo indol al que están unidos forman un heterociclo de 6 miembros que está opcionalmente sustituido con residuos seleccionados de entre =O, C(O)O-alquilo C1-6 o alquilo C1-6; R7 es hidrogeno o alquilo C1-6; R8 es H, halo, metilo, metoxi, CF3, o OCF3; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127334 | 2006-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064547A1 true AR064547A1 (es) | 2009-04-08 |
Family
ID=39201403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105915A AR064547A1 (es) | 2006-12-29 | 2007-12-27 | Derivados de azaspiro como antagonistas del receptor v1a |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8044202B2 (es) |
| EP (1) | EP2125827B1 (es) |
| JP (1) | JP2010514727A (es) |
| KR (1) | KR101129861B1 (es) |
| CN (1) | CN101589046B (es) |
| AR (1) | AR064547A1 (es) |
| AT (1) | ATE486877T1 (es) |
| AU (1) | AU2007341379B2 (es) |
| BR (1) | BRPI0720827A2 (es) |
| CA (1) | CA2674154A1 (es) |
| CL (1) | CL2007003832A1 (es) |
| DE (1) | DE602007010359D1 (es) |
| DK (1) | DK2125827T3 (es) |
| ES (1) | ES2351949T3 (es) |
| MX (1) | MX2009006921A (es) |
| NO (1) | NO20092342L (es) |
| PE (1) | PE20081844A1 (es) |
| PL (1) | PL2125827T3 (es) |
| PT (1) | PT2125827E (es) |
| RU (1) | RU2009124419A (es) |
| TW (1) | TW200835483A (es) |
| WO (1) | WO2008080844A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009119394A (ru) * | 2006-12-07 | 2011-01-20 | Ф. Хоффманн-Ля Рош Аг (Ch) | Производные спиро-пиперидина в качестве антагонистов рецептора v1a |
| CA2673307A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffman-La Roche Ag | Spiro-piperidine derivatives |
| CA2766100C (en) | 2009-06-29 | 2018-05-22 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| EP2548864B1 (en) | 2011-07-22 | 2014-02-19 | Université Joseph Fourier | Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug |
| KR102131612B1 (ko) | 2011-09-02 | 2020-07-08 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| CN102568615B (zh) * | 2011-12-13 | 2013-05-22 | 华中科技大学 | 一种小型精密调平装置 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| SI3831833T1 (sl) | 2015-02-27 | 2023-03-31 | Incyte Holdings Corporation | Postopki za pripravo inhibitorja PI3K |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| EP4051682A1 (en) | 2019-10-29 | 2022-09-07 | Biogen MA Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761992B1 (fr) * | 1997-04-09 | 1999-06-11 | Hoechst Marion Roussel Inc | Nouveaux steroides 4-halogenes, leur procede et intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2005063754A1 (en) * | 2003-12-22 | 2005-07-14 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
-
2007
- 2007-12-19 AT AT07857806T patent/ATE486877T1/de active
- 2007-12-19 KR KR1020097015840A patent/KR101129861B1/ko not_active Expired - Fee Related
- 2007-12-19 WO PCT/EP2007/064183 patent/WO2008080844A1/en not_active Ceased
- 2007-12-19 ES ES07857806T patent/ES2351949T3/es active Active
- 2007-12-19 CA CA002674154A patent/CA2674154A1/en not_active Abandoned
- 2007-12-19 AU AU2007341379A patent/AU2007341379B2/en not_active Expired - Fee Related
- 2007-12-19 PL PL07857806T patent/PL2125827T3/pl unknown
- 2007-12-19 JP JP2009543443A patent/JP2010514727A/ja active Pending
- 2007-12-19 RU RU2009124419/04A patent/RU2009124419A/ru not_active Application Discontinuation
- 2007-12-19 PT PT07857806T patent/PT2125827E/pt unknown
- 2007-12-19 BR BRPI0720827-8A patent/BRPI0720827A2/pt not_active IP Right Cessation
- 2007-12-19 DK DK07857806.9T patent/DK2125827T3/da active
- 2007-12-19 MX MX2009006921A patent/MX2009006921A/es active IP Right Grant
- 2007-12-19 DE DE602007010359T patent/DE602007010359D1/de active Active
- 2007-12-19 EP EP07857806A patent/EP2125827B1/en not_active Not-in-force
- 2007-12-19 CN CN2007800479989A patent/CN101589046B/zh not_active Expired - Fee Related
- 2007-12-20 US US11/960,799 patent/US8044202B2/en not_active Expired - Fee Related
- 2007-12-20 US US11/960,779 patent/US8034937B2/en not_active Expired - Fee Related
- 2007-12-20 US US11/960,823 patent/US8039624B2/en not_active Expired - Fee Related
- 2007-12-26 TW TW096150410A patent/TW200835483A/zh unknown
- 2007-12-27 CL CL200703832A patent/CL2007003832A1/es unknown
- 2007-12-27 AR ARP070105915A patent/AR064547A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000047A patent/PE20081844A1/es not_active Application Discontinuation
-
2009
- 2009-06-18 NO NO20092342A patent/NO20092342L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2125827B1 (en) | 2010-11-03 |
| US8034937B2 (en) | 2011-10-11 |
| AU2007341379A1 (en) | 2008-07-10 |
| RU2009124419A (ru) | 2011-02-10 |
| US20080161333A1 (en) | 2008-07-03 |
| KR20090094172A (ko) | 2009-09-03 |
| CN101589046A (zh) | 2009-11-25 |
| MX2009006921A (es) | 2009-07-06 |
| TW200835483A (en) | 2008-09-01 |
| US20080161332A1 (en) | 2008-07-03 |
| NO20092342L (no) | 2009-07-02 |
| CN101589046B (zh) | 2011-09-21 |
| CA2674154A1 (en) | 2008-07-10 |
| PT2125827E (pt) | 2010-11-22 |
| EP2125827A1 (en) | 2009-12-02 |
| DE602007010359D1 (de) | 2010-12-16 |
| AU2007341379B2 (en) | 2012-05-24 |
| PL2125827T3 (pl) | 2011-04-29 |
| JP2010514727A (ja) | 2010-05-06 |
| US20080281103A1 (en) | 2008-11-13 |
| US8039624B2 (en) | 2011-10-18 |
| KR101129861B1 (ko) | 2012-04-24 |
| PE20081844A1 (es) | 2009-01-26 |
| US8044202B2 (en) | 2011-10-25 |
| ES2351949T3 (es) | 2011-02-14 |
| ATE486877T1 (de) | 2010-11-15 |
| CL2007003832A1 (es) | 2008-07-25 |
| DK2125827T3 (da) | 2010-12-20 |
| BRPI0720827A2 (pt) | 2014-03-04 |
| WO2008080844A1 (en) | 2008-07-10 |
| WO2008080844A9 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR048241A1 (es) | Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c . | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| AR047903A1 (es) | Compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c | |
| AR047902A1 (es) | Compuestos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR048023A1 (es) | Cetoamidas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR047901A1 (es) | Inhibidores de proteasa ns3 del virus de la hepatitis c | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR053186A1 (es) | Derivados del 1- bencil indol carboxamida | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| AR035668A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos | |
| AR037008A1 (es) | El uso del antagonista del receptor nk-1 para la elaboracion de un medicamento para el tratamiento y/o prevencion de lesiones cerebrales, espinales o neuronales y una composicion farmaceutica que comprende uno o mas de dicho antagonista. | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |